Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Iron Overload|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer
Interventions: DRUG: deferasirox
Sponsor: Masonic Cancer Center, University of Minnesota